RNA Therapy Clinical Trials Market Size, Share & Trends Report

RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Modality, By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-4-68040-100-2
Number of Report Pages: 150
Format: PDF, Horizon Databook

Historical Range: 2018 - 2021
Forecast Period: 2023 - 2030
Industry: Healthcare

Market Segmentation

RNA Therapy Clinical Trials Modality Outlook (Revenue, USD Million, 2018 - 2030)
- RNA interference
- Antisense therapy
- Messenger RNA
- Oligonucleotide, non-antisense, non-RNAi
RNA Therapy Clinical Trials Phase Outlook (Revenue, USD Million, 2018 – 2030)
- Phase I
- Phase II
- Phase III
- Phase IV
RNA Therapy Clinical Trials Therapeutic Areas Outlook (Revenue, USD Million, 2018 - 2030)
- Rare Diseases
- Anti-infective
- Anticancer
- Neurological
- Alimentary/Metabolic
- Musculoskeletal
- Cardiovascular Respiratory
- Sensory
- Others
RNA Therapy Clinical Trials Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America RNA Therapy Clinical Trials Market, By Country
    - U.S.
    - Canada
  - North America RNA Therapy Clinical Trials Market, By Modality
    - RNA interference
    - Antisense therapy
    - Messenger RNA
    - Oligonucleotide, non-antisense, non-RNAi
  - North America RNA Therapy Clinical Trials Market, By Clinical Trials
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - North America RNA Therapy Clinical Trials Market, By Therapeutic Areas
    - Rare Diseases
    - Anti-infective
    - Anticancer
    - Neurological
    - Alimentary/Metabolic
    - Musculoskeletal
    - Cardiovascular Respiratory
    - Sensory
    - Others
  - U.S.
    - U.S. RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - U.S. RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - U.S. RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - Canada
    - Canada RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - Canada RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Canada RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
- Europe
  - Europe RNA Therapy Clinical Trials Market, By Country
    - Europe
    - UK
    - Germany
    - France
    - Italy
    - Spain
    - Sweden
    - Norway
    - Denmark
- Asia Pacific
  - Asia Pacific RNA Therapy Clinical Trials Market, By Country
    - Japan
    - China
    - India
    - South Korea
    - Australia
    - Thailand
  - Asia Pacific RNA Therapy Clinical Trials Market, By Modality
    - RNA interference
    - Antisense therapy
    - Messenger RNA
    - Oligonucleotide, non-antisense, non-RNAi
  - Asia Pacific RNA Therapy Clinical Trials Market, By Clinical Trials
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - Asia Pacific RNA Therapy Clinical Trials Market, By Therapeutic Areas
    - Rare Diseases
    - Anti-infective
    - Anticancer
    - Neurological
    - Alimentary/Metabolic
    - Musculoskeletal
    - Cardiovascular Respiratory
    - Sensory
    - Others
  - Japan
    - Japan RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - Japan RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Japan RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - China
    - China RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - China RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - China RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - India
    - India RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - India RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - India RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - South Korea
    - South Korea RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - South Korea RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - South Korea RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - Australia
    - Australia RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - Australia RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Australia RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - Thailand
    - Thailand RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - Thailand RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Thailand RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
- Latin America
- Middle East & Africa
  - Middle East & Africa RNA Therapy Clinical Trials Market, By Country
    - South Africa
    - Saudi Arabia
    - UAE
    - Kuwait
  - Middle East & Africa RNA Therapy Clinical Trials Market, By Modality
    - RNA interference
    - Antisense therapy
    - Messenger RNA
    - Oligonucleotide, non-antisense, non-RNAi
  - Middle East & Africa RNA Therapy Clinical Trials Market, By Clinical Trials
    - Phase I
    - Phase II
    - Phase III
    - Phase IV
  - Middle East & Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas
    - Rare Diseases
    - Anti-infective
    - Anticancer
    - Neurological
    - Alimentary/Metabolic
    - Musculoskeletal
    - Cardiovascular Respiratory
    - Sensory
    - Others
  - South Africa
    - South Africa RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - South Africa RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - South Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - Saudi Arabia
    - Saudi Arabia RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - Saudi Arabia RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Saudi Arabia RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - UAE
    - UAE RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - UAE RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - UAE RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others
  - Kuwait
    - Kuwait RNA Therapy Clinical Trials Market, By Modality
      - RNA interference
      - Antisense therapy
      - Messenger RNA
      - Oligonucleotide, non-antisense, non-RNAi
    - Kuwait RNA Therapy Clinical Trials Market, By Clinical Trials
      - Phase I
      - Phase II
      - Phase III
      - Phase IV
    - Kuwait RNA Therapy Clinical Trials Market, By Therapeutic Areas
      - Rare Diseases
      - Anti-infective
      - Anticancer
      - Neurological
      - Alimentary/Metabolic
      - Musculoskeletal
      - Cardiovascular Respiratory
      - Sensory
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.